University Hospital of Cologne

One full-time Post-doctoral

University Hospital of Cologne

Cologne, Germany

As a modern maximum-care hospital with a capacity of approximately 1,540 beds, the University Hospital of Cologne is dedicated to the practice of innovative academic medical excellence and assumes important societal functions in the fields of research, education and health care. The University Hospital of Cologne provides treatment to over 340,000 patients annually, with 60,300 of them receiving inpatient care. With more than 10.700 employees from over 80 nations the University Hospital of Cologne is one of the largest employers in Cologne and ranks among the leading university clinics in Germany.

The Center for Molecular Medicine Cologne invites applications from enthusiastic, motivated individuals for the Junior Research Group (JRG XII) “Cell Death, Inflammation and Immunity” of Dr. Alessandro Annibaldi for:

One full-time Post-doctoral researcher

(100% TV-L)

This position is immediately available for 36 months by Third-party funding according to WissZeitVG with a possibility of extension.

The Center for Molecular Medicine Cologne (CMMC) is a multidisciplinary center at the University of Cologne providing a forum that brings together physician scientists with basic researchers from the Faculty of Medicine and the Faculty of Mathematics and Natural Sciences to perform competitive basic, disease-oriented research. The mission of the CMMC is to advance the understanding of the underlying molecular and cellular mechanisms as a prelude to improving prevention, diagnosis and treatment of many common health problems.

For further information, please visit ZMMK.

Research overview:
We are interested in the role of cell death in health and disease. The main focus of this work is Immunogenic Cell Death (ICD), to understand how dying cancer cells can activate anti-tumour immune responses. It is now clear that dying cancer cells play an active role in the initiation of an anti-tumour immune response. However, there are multiple ways in which a cell can die, and not every type of death can stimulate an anti-tumour immune response. Indeed, while certain types of cell death are characterized by the production and release of immunogenic factors, being therefore immunogenic, others are immunologically silent.

Our starting point will be RIPK1, a kinase that controls different types of cell death (i.e. apoptosis and necroptosis) as well ad the production of immunogenic factors. Additionally, we will focus on other forms of cell death whose immunogenic potential is still unknown.

We will use a series of in vitro cell models, genetic and transplantable mouse cancer models of melanoma and samples from melanoma patients to address how cell death influence anti-tumour immunity and the mechanisms underlying the induction of immunogenic cell death.

Understanding how immunogenic cell death is executed and how this activates the immune system against malignant cells might help the design of therapies to circumvent resistance to the current immunotherapies.

Required skills and qualifications:

  • PhD in biochemistry, biophysics or a related field
  • Advanced experience and publication record in immunology and cell death
  • Excellent expertise in immunology and analysis of immune cell types and subtypes
  • Knowledge of different cell death pathways
  • Ability to independently drive research projects
  • High level of motivation, enthusiasm, endurance and positivity
  • Ability and willingness to work in a collaborative team
  • Excellent communication in English (written and speech)

Desired qualifications:

  • Experience in mouse handling and mouse tumour models (e.g. genetic and transplantation-based models)
  • Experience in immuno-staining of mouse and human samples
  • Experience with image analysis and staining quantification softwares (e.g. QuPath)

Your responsibilities will include:

  • Culture of mouse and human melanoma cell lines, primary and immortalized mouse and human melanocytes
  • Analysis of tumour-infiltrating immune cell types and subtypes
  • Immuno-staining of human and mouse tumour sections (IHC and IF)
  • Generation of CRISPR-Cas9 edited cell lines
  • Biochemical analysis of cell death signalling pathways
  • Design and execution of in vivo tumour studies using the mouse as model system
  • Conduct collaborative efforts across disciplines

We offer:

  • Jobticket
  • A vibrant sceintific environment

Your salary will be based on TV-L.

Applications from female candidates are welcome; suitably qualified women will be given preferential consideration unless other applicants clearly demonstrate superior qualifications.

We also welcome applications from candidates with disabilities, who will also be given preferential consideration over other applicants with comparable qualifications.

The position is suitable for staffing with part-time employees.

Please address enquiries to Dr. Annibaldi via email ( a.annibaldi@qmul.ac.uk ).

Have we awakened your interest? Please submit your application (including a detailed CV, list of publications, two references and a brief statement of research interests) as a single Pdf-document by e-mail quoting the reference number here.

Uniklinik Köln
Geschäftsbereich Personal
BewerbungsManagement
Number of job posting: V000001366
50924 Köln

Favorite

Apply with CV and Cover Letter

Must be a .doc, .docx, or .pdf file and no larger than 1MBMust be a .doc, .docx, or .pdf file and no larger than 1MB
Position

One full-time Post-doctoral